A carregar...
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
CPX-351 is a liposomal formulation of cytarabine:daunorubicin designed to deliver synergistic drug ratios to leukemia cells. In this phase 2 study, newly diagnosed older acute myeloid leukemia (AML) patients were randomized 2:1 to first-line CPX-351 or 7+3 treatment. The goal was to determine effica...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4624448/ https://ncbi.nlm.nih.gov/pubmed/24687088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-540971 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|